Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Lengauer

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Science (New York, N.Y.)|August 8, 2009
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cellsJihye Yun, Carlo Rago, Ian Cheong, et al.
Nature|August 12, 2005
Colorectal cancer: mutations in a signalling pathwayD Williams Parsons, Tian-Li Wang, Yardena Samuels, et al.
Oncotarget|May 17, 2014
Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistanceShih-Min A Huang, Anlai Wang, Rita Greco, et al.
Bioorganic & Medicinal Chemistry Letters|February 25, 2014
Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kβ inhibitorsVictor Certal, Frank Halley, Angela Virone-Oddos, et al.
Cancer Discovery|October 3, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular CarcinomaMegan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.
Gastro Hep Advances|August 12, 2024
Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar CarcinomaStefanie S Schalm, Erin O'Hearn, Kevin Wilson, et al.
Blood|July 10, 2014
PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogeneZhuyan Guo, Anlai Wang, Weidong Zhang, et al.
Cancer Research|May 6, 2004
Three classes of genes mutated in colorectal cancers with chromosomal instabilityZhenghe Wang, Jordan M Cummins, Dong Shen, et al.
Bioorganic & Medicinal Chemistry Letters|September 18, 2012
Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitorsVictor Certal, Frank Halley, Angela Virone-Oddos, et al.
The Journal of Biological Chemistry|September 5, 2013
Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approachesQiang Gao, Ingrid Mechin, Nayantara Kothari, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Science (New York, N.Y.)|August 8, 2009
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cellsJihye Yun, Carlo Rago, Ian Cheong, et al.
Nature|August 12, 2005
Colorectal cancer: mutations in a signalling pathwayD Williams Parsons, Tian-Li Wang, Yardena Samuels, et al.
Oncotarget|May 17, 2014
Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistanceShih-Min A Huang, Anlai Wang, Rita Greco, et al.
Bioorganic & Medicinal Chemistry Letters|February 25, 2014
Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kβ inhibitorsVictor Certal, Frank Halley, Angela Virone-Oddos, et al.
Cancer Discovery|October 3, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular CarcinomaMegan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.
Gastro Hep Advances|August 12, 2024
Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar CarcinomaStefanie S Schalm, Erin O'Hearn, Kevin Wilson, et al.
Blood|July 10, 2014
PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogeneZhuyan Guo, Anlai Wang, Weidong Zhang, et al.
Cancer Research|May 6, 2004
Three classes of genes mutated in colorectal cancers with chromosomal instabilityZhenghe Wang, Jordan M Cummins, Dong Shen, et al.
Bioorganic & Medicinal Chemistry Letters|September 18, 2012
Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitorsVictor Certal, Frank Halley, Angela Virone-Oddos, et al.
The Journal of Biological Chemistry|September 5, 2013
Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approachesQiang Gao, Ingrid Mechin, Nayantara Kothari, et al.
Pageof 8